Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-12-29

Clinical Trial Update: Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1% [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic study comparing systemic exposure of Differin Gel 0.3% vs 0.1% in acne vulgaris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Differin Gel (adapalene)

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 4 | Status: COMPLETED | Results posted: 2009-12-29